Blueprint Medicines: Hold Rating Amidst Future Research Potential and Clinical Uncertainties
Blueprint Medicines (BPMC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Blueprint Medicines’ Promising Pipeline Developments Support Buy Rating
Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst
JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...
Fintel on MSN16h
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation
Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...